XtalPi

Research on the record

• 2026-10-15XtalPi names its first siRNA drug candidate, for IgA nephropathy, nine months after the programme began on its Kodexia platformLevel 4 · Tested in the physical world
• 2026-10-06XtalPi debuts a closed-loop siRNA design platform and says six of its own programmes now run on it, the first reaching monkey data in 7 monthsLevel 4 · Tested in the physical world
• 2026-10-02XtalPi moves its own AI- and robot-designed hair-loss drug into IND-enabling studies after a mouse result it compares with minoxidilLevel 4 · Tested in the physical world
• 2026-09-21XtalPi opens more than 80 in-house drug-discovery tools to its science agent and lets it schedule the company's lab robotsLevel 1 · Exists
• 2026-09-15XtalPi's LCMS2Yield predicts how strongly a reaction product absorbs UV light, so its yield can be measured without first purifying a reference sampleLevel 3 · Checked against existing evidence

Graded by how far the evidence went, not how good the result is. See the methodology.

Also on the timeline

• 2026-09-16Apex Intelligence raises nearly $50M across two rounds to build a self-improving AI researcherCapital
• 2026-09-10Rhinovate raises a Pre-A round in the hundreds of millions of yuan for AI-run materials labsCapital
• 2026-06-09XtalPi signs an unnamed international drugmaker to an oral small-molecule programme for a GPCR target, with a potential total value over $400MPartnerships

People

Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.

Funding rounds tracked

• 2025-09-04Placing · about HK$2,653.3M grossconfirmedStated use: R&D, commercialisation, acquisitions and working capital
• 2025-02-25Placing · about HK$2,088M grossconfirmedStated use: R&D, data and models, commercialisation, acquisitions
• 2025-01-24Placing · about HK$1,130M grossconfirmedStated use: R&D, commercialisation, investments and working capital
• 2024-06-13IPO · about HK$989.3M gross, pre-greenshoeconfirmedAnchored by Successful Lotus (Peter Lee Ka-kit), IntelliMed, Mammoth Medical Solutions, Begonia No. 1 LPF, Bradley L. Pentelute, Ginkgo Fund I, Biocytogen, FaaS Capital Longevity LimitedStated use: R&D, commercialisation and working capital

Each round links to its line on the funding record, with its source.

Also in Drug discovery on the funding board

The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.

• 2026-10-29ALLOXSeed · US$10.5M (€9.4M)Measures the effects of thousands of protein mutations at once to map allosteric and other regulatory sites, and builds AI models on that data to find drug-binding spots on hard targets such as protein-protein interactions and transcription factors, for its own small molecules.
• 2026-10-27Atlas BioSeed · $10MRuns in silico clinical trials, starting in immunology: a foundation model trained on about 2 million RNA readouts from human tissue predicts each virtual patient's response to several treatments and diseases, to help drug developers choose what to take into Phase II.
• 2026-10-23Pathos AISeries E · $237MLicenses clinical-stage drugs from other companies and develops them itself, using an agent platform (Foundry, earlier PathOS) trained on patient records to choose assets, pick the patients most likely to respond and adjust trials as they run. Its pipeline is in cancer: prostate cancer, multiple myeloma, lung and breast cancer and TROP2/HER3-expressing solid tumours; in October 2026 it began work in Alzheimer's disease with Bristol Myers Squibb and Tempus.
• 2026-10-23Zhichong PharmaSeries A1 · tens of millions of yuanDevelops new drugs for pets with generative AI, using its own small-molecule and large-molecule design engines (ChemoFetch and OmniFetch), and argues that testing in the target animal closes the loop from design to evidence faster than human drug development can; its programmes are in anti-infectives, chronic disease and ageing.
• 2026-10-14Gaowei YiyaoPre-A · undisclosed; PEdaily says the company has raised several hundred million yuan so far this yearMines protein-interaction and other high-dimensional biology data with its own models to find drug targets others treat as undruggable, then runs its own small-molecule and antibody programmes. Its GROOVY platform found the target behind GW-01, a Notch-pathway inhibitor now in Phase I; ACUMEN maps pairs of neighbouring cell-surface proteins for bispecifics and NEXUS looks for tumour neoantigens.
• 2026-10-14Iambic TherapeuticsIPO · $150MDesigns small-molecule cancer drugs with AI structure-prediction models (NeuralPLexer) linked to an automated chemistry and biology lab.

All 37 in this field →